Research Support Centre
Search
Technology Platforms

Fragment Based Screening by Experimental Drug Development Centre (EDDC)

Fragment Based Screening (FBS) is a validated approach towards finding high quality hits against challenging proteins that are classified as undruggable. A team of experts at the FBS employ proprietary library and a cascade of biophysical techniques, to find ligand efficient fragment hits against targets in the oncology and infectious disease space.

The fragment library @ FBS covers a wide range of chemical spaces and is suitable for diverse targets such as DNA Gyrase and undruggable targets such as protein-protein interactions. The screening methods are able to identify fragments binding weakly to the target (affinity in mM range). EDDC has diverse methodologies to monitor fragment growth, which can be achieved through measuring binding affinities, activities or competition assays.

In summary, FBS offers expertise for projects involving fragment identification using binding and competition assays, characterization of protein-fragment interactions, map the ligand binding site, designing fragment growth and target-lead interactions.

 

Key Services

  • Fragment identification  
  • Target-ligand interaction analysis 
  • Novel compound design
  • Diverse screening method design  

 

Expertise in Diverse Targets 

  • Kinases 
  • Proteases 
  • Methyltransferases 
  • Targets with shallow pockets 
  • Protein complexes 
  • Membrane proteins 

 

Key Technologies

  • Differential scanning fluorimetry  
  • Ligand-observed NMR spectroscopy  
  • Protein-observed NMR spectroscopy
  • Targets with shallow pockets 
  • Fluorescence polarization
  • Surface Plasmon Resonance 
  • Isothermal Titration Calorimetry  
  • Protein manufacture  
  • Multiple protein-label strategies 

 

Different types of methods are available to probe target-ligand interactions. Protein-observed and ligand observed solution NMR experiments are utilized to screen fragments, confirm fragment hits identified using other methods and map the fragment bind sites for certain targets with a molecular weight less than 30 kDa. This figure shows the application of STD-NMR and 19F-NMR in fragment screening and hit confirmation.

 

Some of the research publications produced by EDDC FBS 

 

 

Structural Biology & Biophysical Screening consisting of Fragment Based Screening (FBS) and Protein crystallography (XRAY) is part of the EDDC Academic Research Organisation or EARO, a Fee-for-Service initiative by the Experimental Drug Development Centre (EDDC). Founded in 2020, EARO was conceived to provide greater access to EDDC’s rich scientific expertise and state of the art technology platforms to the academic and industry researchers in the biomedical ecosystem who aspire to embark on a journey of translating their research into drug candidates. EARO comprises primarily of 5 core drug discovery platforms headed by scientists with decades of experience.  The EARO Platforms include High Throughput Screening (HTS), Fragment Based Screening (FBS), Protein Crystallography (XRAY), High Throughput Phenomics (HTP) and Computational Phenomics Platforms (CPP). Together, EARO groups have engaged with more than 70 academic and industry partners.

 
Visit https://www.a-star.edu.sg/eddc for more information  or email enquiries@rsc.a-star.edu.sg